Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Accumulated Expenses (2022 - 2025)

Praxis Precision Medicines has reported Accumulated Expenses over the past 4 years, most recently at $35.0 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $35.0 million for Q4 2025, up 47.43% from a year ago — trailing twelve months through Dec 2025 was $35.0 million (up 47.43% YoY), and the annual figure for FY2025 was $35.0 million, up 47.43%.
  • Accumulated Expenses for Q4 2025 was $35.0 million at Praxis Precision Medicines, up from $21.6 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for PRAX hit a ceiling of $35.0 million in Q4 2025 and a floor of $7.0 million in Q1 2024.
  • Median Accumulated Expenses over the past 4 years was $15.7 million (2022), compared with a mean of $17.2 million.
  • Biggest five-year swings in Accumulated Expenses: crashed 69.76% in 2023 and later surged 220.43% in 2024.
  • Praxis Precision Medicines' Accumulated Expenses stood at $15.8 million in 2022, then plummeted by 53.21% to $7.4 million in 2023, then surged by 220.43% to $23.8 million in 2024, then skyrocketed by 47.43% to $35.0 million in 2025.
  • The last three reported values for Accumulated Expenses were $35.0 million (Q4 2025), $21.6 million (Q3 2025), and $19.0 million (Q2 2025) per Business Quant data.